Clinical Trial Update: Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating low dose intravenous ketamine for treatment-resistant depression has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Treatment Resistant Depression | Phase 2 | Status: COMPLETED | Results posted: 2020-08-31